{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:33:18Z","timestamp":1761129198788},"reference-count":92,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["id.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Disease Clinics of North America"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.idc.2014.11.005","type":"journal-article","created":{"date-parts":[[2015,1,5]],"date-time":"2015-01-05T14:19:25Z","timestamp":1420467565000},"page":"93-108","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Treatment of Clostridium difficile Infections"],"prefix":"10.1016","volume":"29","author":[{"given":"Melinda M.","family":"Soriano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8083","key":"10.1016\/j.idc.2014.11.005_bib1","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0140-6736(78)91741-5","article-title":"Oral vancomycin for antibiotic-associated pseudomembranous colitis","volume":"2","author":"Tedesco","year":"1978","journal-title":"Lancet"},{"issue":"8358","key":"10.1016\/j.idc.2014.11.005_bib2","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0140-6736(83)91036-X","article-title":"Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis","volume":"2","author":"Teasley","year":"1983","journal-title":"Lancet"},{"issue":"RR\u201312","key":"10.1016\/j.idc.2014.11.005_bib3","first-page":"1","article-title":"Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC)","volume":"44","year":"1995","journal-title":"MMWR Recomm Rep"},{"issue":"8","key":"10.1016\/j.idc.2014.11.005_bib4","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2307\/30141083","article-title":"Clostridium difficile-associated diarrhea and colitis","volume":"16","author":"Gerding","year":"1995","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"4","key":"10.1016\/j.idc.2014.11.005_bib5","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/jac\/36.4.673","article-title":"Diarrhoea caused by Clostridium difficile: response time for treatment with metronidazole and vancomycin","volume":"36","author":"Wilcox","year":"1995","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.idc.2014.11.005_bib6","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1086\/588293","article-title":"Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin","volume":"47","author":"Al-Nassir","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2014.11.005_bib7","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1086\/519265","article-title":"A\u00a0comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity","volume":"45","author":"Zar","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2014.11.005_bib8","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1086\/651706","article-title":"Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)","volume":"31","author":"Cohen","year":"2010","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"3","key":"10.1016\/j.idc.2014.11.005_bib9","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/cid\/ciu313","article-title":"Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials","volume":"59","author":"Johnson","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"Suppl 22","key":"10.1016\/j.idc.2014.11.005_bib10","first-page":"41","article-title":"Therapeutic trials of antibiotic associated colitis","author":"Mogg","year":"1980","journal-title":"Scand J Infect Dis Suppl"},{"issue":"4","key":"10.1016\/j.idc.2014.11.005_bib11","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1086\/506351","article-title":"Nitazoxanide for the treatment of Clostridium difficile colitis","volume":"43","author":"Musher","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2014.11.005_bib12","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa0910812","article-title":"Fidaxomicin versus vancomycin for Clostridium difficile infection","volume":"364","author":"Louie","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.idc.2014.11.005_bib13","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1473-3099(11)70374-7","article-title":"Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial","volume":"12","author":"Cornely","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"10.1016\/j.idc.2014.11.005_bib14","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1128\/AAC.00605-12","article-title":"Sustained clinical response as an endpoint in treatment trials of Clostridium difficile-associated diarrhea","volume":"56","author":"Johnson","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2014.11.005_bib15","series-title":"Kucers' The use of antibiotics sixth edition","author":"Grayson","year":"2010"},{"issue":"Suppl 24","key":"10.1016\/j.idc.2014.11.005_bib16","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1038\/1841894b0","article-title":"Selective inhibition of ribonucleic acid synthesis in Staphylococcus aureus by vancomycin","volume":"184","author":"Jordan","year":"1959","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.idc.2014.11.005_bib17","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/01.smj.0000216477.06918.a3","article-title":"Significant absorption of oral vancomycin in a patient with Clostridium difficile colitis and normal renal function","volume":"99","author":"Aradhyula","year":"2006","journal-title":"South Med J"},{"issue":"2","key":"10.1016\/j.idc.2014.11.005_bib18","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3109\/00365548.2010.513066","article-title":"Oral vancomycin may have significant absorption in patients with Clostridium difficile colitis","volume":"43","author":"Chihara","year":"2011","journal-title":"Scand J Infect Dis"},{"issue":"4","key":"10.1016\/j.idc.2014.11.005_bib19","doi-asserted-by":"crossref","first-page":"297","DOI":"10.7326\/0003-4819-117-4-297","article-title":"Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial","volume":"117","author":"Johnson","year":"1992","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.idc.2014.11.005_bib20","doi-asserted-by":"crossref","first-page":"e76269","DOI":"10.1371\/journal.pone.0076269","article-title":"Defining the vulnerable period for re-establishment of Clostridium difficile colonization after treatment of C. difficile infection with oral vancomycin or metronidazole","volume":"8","author":"Abujamel","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.idc.2014.11.005_bib21","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1186\/1471-2334-10-363","article-title":"Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection","volume":"10","author":"Gonzales","year":"2010","journal-title":"BMC Infect Dis"},{"issue":"10","key":"10.1016\/j.idc.2014.11.005_bib22","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1086\/587656","article-title":"Vancomycin for the treatment of Clostridium difficile infection: for whom is this expensive bullet really magic?","volume":"46","author":"Pepin","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2014.11.005_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0732-8893(98)00139-4","article-title":"Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and etest","volume":"34","author":"Wong","year":"1999","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2014.11.005_bib24","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1128\/AAC.50.5.1890-1892.2006","article-title":"Antimicrobial susceptibility pattern of Clostridium difficile and its relation to PCR ribotypes in a Swedish University Hospital","volume":"50","author":"Aspevall","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.idc.2014.11.005_bib25","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0002-9343(89)90223-4","article-title":"Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens","volume":"86","author":"Fekety","year":"1989","journal-title":"Am J Med"},{"key":"10.1016\/j.idc.2014.11.005_bib26","unstructured":"Vancocin\u00ae [package insert]. ViroPharma Incorporated. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/050606s028lbl.pdf. Accessed September 29, 2014."},{"issue":"6","key":"10.1016\/j.idc.2014.11.005_bib27","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ijantimicag.2013.08.013","article-title":"Effect of vancomycin dose on treatment outcomes in severe Clostridium difficile infection","volume":"42","author":"Lam","year":"2013","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl 2","key":"10.1016\/j.idc.2014.11.005_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/1469-0691.12418","article-title":"European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection","volume":"20","author":"Debast","year":"2014","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"10.1016\/j.idc.2014.11.005_bib29","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1001\/archinte.1986.00360180083015","article-title":"Oral bacitracin vs vancomycin therapy for Clostridium difficile-induced diarrhea. A randomized double-blind trial","volume":"146","author":"Dudley","year":"1986","journal-title":"Arch Intern Med"},{"issue":"10","key":"10.1016\/j.idc.2014.11.005_bib30","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1128\/AAC.36.10.2192","article-title":"Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea","volume":"36","author":"de Lalla","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.idc.2014.11.005_bib31","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1093\/cid\/cir830","article-title":"Fidaxomicin: a novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection","volume":"54","author":"Venugopal","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.idc.2014.11.005_bib32","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1128\/AAC.01045-07","article-title":"Safety, tolerance, and pharmacokinetic studies of opt-80 in healthy volunteers following single and multiple oral doses","volume":"52","author":"Shue","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.idc.2014.11.005_bib33","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1128\/AAC.01443-07","article-title":"Opt-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection","volume":"53","author":"Louie","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"Pt 11","key":"10.1016\/j.idc.2014.11.005_bib34","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1099\/mic.0.042010-0","article-title":"A\u00a0new macrocyclic antibiotic, fidaxomicin (opt-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin","volume":"156","author":"Tannock","year":"2010","journal-title":"Microbiology (Reading, England)"},{"issue":"Suppl 2","key":"10.1016\/j.idc.2014.11.005_bib35","doi-asserted-by":"crossref","first-page":"S162","DOI":"10.1093\/cid\/cis453","article-title":"Fidaxomicin inhibits spore production in Clostridium difficile","volume":"55","author":"Babakhani","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2014.11.005_bib36","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/jac\/dks450","article-title":"Fidaxomicin inhibits toxin production in Clostridium difficile","volume":"68","author":"Babakhani","year":"2013","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"9","key":"10.1016\/j.idc.2014.11.005_bib37","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1128\/AAC.00104-11","article-title":"Postantibiotic effect of fidaxomicin and its major metabolite, op-1118, against Clostridium difficile","volume":"55","author":"Babakhani","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2014.11.005_bib38","unstructured":"Dificid\u00ae [package insert]. San Diego, CA: Optimer Pharmaceuticals, Inc; 2011."},{"issue":"8","key":"10.1016\/j.idc.2014.11.005_bib39","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1586\/14787210.2013.814767","article-title":"Fidaxomicin: a minimally absorbed macrocyclic antibiotic for the treatment of Clostridium difficile infections","volume":"11","author":"Soriano","year":"2013","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"19","key":"10.1016\/j.idc.2014.11.005_bib40","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2012.45.5899","article-title":"Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin","volume":"31","author":"Cornely","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.idc.2014.11.005_bib41","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/jgs.12090","article-title":"Effect of age on treatment outcomes in Clostridium difficile infection","volume":"61","author":"Louie","year":"2013","journal-title":"J\u00a0Am Geriatr Soc"},{"issue":"1","key":"10.1016\/j.idc.2014.11.005_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000351757","article-title":"Renal impairment and clinical outcomes of Clostridium difficile infection in two randomized trials","volume":"38","author":"Mullane","year":"2013","journal-title":"Am J Nephrol"},{"issue":"5","key":"10.1016\/j.idc.2014.11.005_bib43","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/cid\/cir404","article-title":"Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections","volume":"53","author":"Mullane","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.idc.2014.11.005_bib44","doi-asserted-by":"crossref","first-page":"5194","DOI":"10.1128\/AAC.00625-11","article-title":"Comparative susceptibilities to fidaxomicin (opt-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection","volume":"55","author":"Goldstein","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.idc.2014.11.005_bib45","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/jac\/5.5.499","article-title":"Mechanism of antimicrobial action of metronidazole","volume":"5","author":"Edwards","year":"1979","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.idc.2014.11.005_bib46","doi-asserted-by":"crossref","first-page":"328","DOI":"10.2165\/00003088-199223050-00002","article-title":"Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives","volume":"23","author":"Lau","year":"1992","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/j.idc.2014.11.005_bib47","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1128\/AAC.8.4.409","article-title":"Unique bactericidal action of metronidazole against Bacteroides fragilis and Clostridium perfringens","volume":"8","author":"Ralph","year":"1975","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.idc.2014.11.005_bib48","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/0732-8893(91)90064-M","article-title":"Comparison of the bactericidal activity of clindamycin and metronidazole against cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides fragilis group","volume":"14","author":"Stratton","year":"1991","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"4","key":"10.1016\/j.idc.2014.11.005_bib49","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1159\/000104471","article-title":"Pharmacodynamic studies of vancomycin, metronidazole and fusidic acid against Clostridium difficile","volume":"53","author":"Odenholt","year":"2007","journal-title":"Chemotherapy"},{"issue":"5","key":"10.1016\/j.idc.2014.11.005_bib50","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/jac\/dkn313","article-title":"Emergence of reduced susceptibility to metronidazole in Clostridium difficile","volume":"62","author":"Baines","year":"2008","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.idc.2014.11.005_bib51","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/jac\/48.5.741","article-title":"Reduced susceptibility of Clostridium difficile to metronidazole","volume":"48","author":"Brazier","year":"2001","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.idc.2014.11.005_bib52","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ijantimicag.2009.09.012","article-title":"Antimicrobial resistance in Clostridium difficile","volume":"34","author":"Huang","year":"2009","journal-title":"Int J Antimicrob Agents"},{"issue":"10","key":"10.1016\/j.idc.2014.11.005_bib53","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1136\/gut.27.10.1169","article-title":"Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile","volume":"27","author":"Bolton","year":"1986","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.idc.2014.11.005_bib54","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1128\/AAC.46.6.1647-1650.2002","article-title":"Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin","volume":"46","author":"Pelaez","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.idc.2014.11.005_bib55","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1128\/JCM.00524-08","article-title":"Metronidazole resistance in Clostridium difficile is heterogeneous","volume":"46","author":"Pelaez","year":"2008","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.idc.2014.11.005_bib56","unstructured":"Pelaez T, Sanchez R, Blazquez R, et\u00a0al. Metronidazole resistance in Clostridium difficile: a new emerging problem? Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Orlando, October 4\u20137, 1994."},{"issue":"Suppl 1","key":"10.1016\/j.idc.2014.11.005_bib57","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000081990","article-title":"Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential","volume":"51","author":"Scarpignato","year":"2005","journal-title":"Chemotherapy"},{"key":"10.1016\/j.idc.2014.11.005_bib58","unstructured":"Xifaxan\u00ae [package insert]. Salix Pharmaceuticals, Inc. Available at: http:\/\/cdn.salix.com\/shared\/pi\/xifaxan550-pi.pdf. Accessed December 2, 2014."},{"issue":"2","key":"10.1016\/j.idc.2014.11.005_bib59","first-page":"74","article-title":"Treatment for colitis caused by Clostridium difficile: results of a randomized open study of rifaximine vs. Vancomycin","volume":"5","author":"Boero","year":"1990","journal-title":"Microbiol Med (Milan)"},{"issue":"12","key":"10.1016\/j.idc.2014.11.005_bib60","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1093\/jac\/dkr377","article-title":"A\u00a0randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection","volume":"66","author":"Garey","year":"2011","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.idc.2014.11.005_bib61","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1086\/511870","article-title":"Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin","volume":"44","author":"Johnson","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2014.11.005_bib62","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.anaerobe.2009.08.004","article-title":"Rifaximin redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment","volume":"15","author":"Johnson","year":"2009","journal-title":"Anaerobe"},{"issue":"4","key":"10.1016\/j.idc.2014.11.005_bib63","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/1756283X10372985","article-title":"Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial","volume":"3","author":"Basu","year":"2010","journal-title":"Therap Adv Gastroenterol"},{"issue":"8","key":"10.1016\/j.idc.2014.11.005_bib64","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1128\/AAC.44.8.2205-2206.2000","article-title":"In\u00a0vitro activity and fecal concentration of rifaximin after oral administration","volume":"44","author":"Jiang","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.idc.2014.11.005_bib65","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000007297","article-title":"In\u00a0vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species","volume":"46","author":"Marchese","year":"2000","journal-title":"Chemotherapy"},{"issue":"3","key":"10.1016\/j.idc.2014.11.005_bib66","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1128\/AAC.01159-06","article-title":"Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, and Campylobacter jejuni","volume":"51","author":"Hoffman","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2014.11.005_bib67","unstructured":"Flagyl\u00ae [package insert]. G.D. Searle. Available at: http:\/\/labeling.pfizer.com\/showlabeling.aspx?id=570. Accessed September 29, 2014."},{"key":"10.1016\/j.idc.2014.11.005_bib68","unstructured":"Alinia\u00ae [package insert]. Romark Laboratories, L.C. Available at: http:\/\/www.romark.com\/images\/stories\/AliniaPrescriptionInformation.pdf. Accessed September 29, 2014."},{"issue":"8","key":"10.1016\/j.idc.2014.11.005_bib69","doi-asserted-by":"crossref","first-page":"387","DOI":"10.5414\/CPP38387","article-title":"Nitazoxanide: pharmacokinetics and metabolism in man","volume":"38","author":"Broekhuysen","year":"2000","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.idc.2014.11.005_bib70","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1128\/AAC.01623-06","article-title":"In\u00a0vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004","volume":"51","author":"Hecht","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.idc.2014.11.005_bib71","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1086\/596552","article-title":"Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study","volume":"48","author":"Musher","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.idc.2014.11.005_bib72","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1093\/jac\/dkl553","article-title":"Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide","volume":"59","author":"Musher","year":"2007","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.idc.2014.11.005_bib73","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/00000658-200203000-00008","article-title":"Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications","volume":"235","author":"Dallal","year":"2002","journal-title":"Ann Surg"},{"issue":"11","key":"10.1016\/j.idc.2014.11.005_bib74","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1002\/bjs.8868","article-title":"Systematic review and meta-analysis of outcomes following emergency surgery for Clostridium difficile colitis","volume":"99","author":"Bhangu","year":"2012","journal-title":"Br J Surg"},{"issue":"1","key":"10.1016\/j.idc.2014.11.005_bib75","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.amjsurg.2009.07.040","article-title":"Surgical aspects of fulminant Clostridium difficile colitis","volume":"200","author":"Butala","year":"2010","journal-title":"Am J Surg"},{"issue":"2","key":"10.1016\/j.idc.2014.11.005_bib76","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.sla.0000236628.79550.e5","article-title":"Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain","volume":"245","author":"Lamontagne","year":"2007","journal-title":"Ann Surg"},{"issue":"4","key":"10.1016\/j.idc.2014.11.005_bib77","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1177\/000313481007600421","article-title":"Colectomy for fulminant Clostridium difficile colitis: predictors of mortality","volume":"76","author":"Perera","year":"2010","journal-title":"Am Surg"},{"issue":"3","key":"10.1016\/j.idc.2014.11.005_bib78","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/SLA.0b013e31822ade48","article-title":"Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease","volume":"254","author":"Neal","year":"2011","journal-title":"Ann Surg"},{"issue":"3","key":"10.1016\/j.idc.2014.11.005_bib79","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1086\/525047","article-title":"Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea","volume":"197","author":"Chang","year":"2008","journal-title":"J\u00a0Infect Dis"},{"issue":"4","key":"10.1016\/j.idc.2014.11.005_bib80","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/cid\/cis495","article-title":"Fidaxomicin failures in recurrent Clostridium difficile infection: a problem of timing","volume":"55","author":"Orenstein","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2014.11.005_bib81","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofu069","article-title":"Novel fidaxomicin treatment regimens for patients with multiple Clostridium difficile infection recurrences that are refractory to standard therapies Open Forum","volume":"1","author":"Soriano","year":"2014","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2014.11.005_bib82","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1086\/501126","article-title":"Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada","volume":"42","author":"Pepin","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2014.11.005_bib83","doi-asserted-by":"crossref","first-page":"361","DOI":"10.7326\/0003-4819-88-3-361","article-title":"Neurologic toxicity associated with high-dose metronidazole therapy","volume":"88","author":"Frytak","year":"1978","journal-title":"Ann Intern Med"},{"issue":"Suppl 2","key":"10.1016\/j.idc.2014.11.005_bib84","doi-asserted-by":"crossref","first-page":"S154","DOI":"10.1093\/cid\/cis462","article-title":"Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin","volume":"55","author":"Cornely","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2014.11.005_bib85","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1086\/506354","article-title":"Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile-associated diarrhea","volume":"43","author":"Lagrotteria","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.idc.2014.11.005_bib86","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1111\/j.1572-0241.2002.05839.x","article-title":"Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease","volume":"97","author":"McFarland","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.idc.2014.11.005_bib87","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/cid\/cis833","article-title":"Fidaxomicin \u201cchaser\u201d regimen following vancomycin for patients with multiple Clostridium difficile recurrences","volume":"56","author":"Johnson","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2014.11.005_bib88","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1056\/NEJMoa1205037","article-title":"Duodenal infusion of donor feces for recurrent Clostridium difficile","volume":"368","author":"van Nood","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.idc.2014.11.005_bib89","doi-asserted-by":"crossref","first-page":"5224","DOI":"10.1128\/AAC.00913-12","article-title":"Evaluation of an oral suspension of vp20621, spores of nontoxigenic Clostridium difficile strain m3, in healthy subjects","volume":"56","author":"Villano","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.idc.2014.11.005_bib90","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ajic.2006.06.007","article-title":"Clinical outcomes of intravenous immune globulin in severe Clostridium difficile-associated diarrhea","volume":"35","author":"Juang","year":"2007","journal-title":"Am J Infect Control"},{"issue":"5","key":"10.1016\/j.idc.2014.11.005_bib91","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1093\/jac\/dkh176","article-title":"Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea","volume":"53","author":"Wilcox","year":"2004","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"8","key":"10.1016\/j.idc.2014.11.005_bib92","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1128\/AAC.45.8.2340-2347.2001","article-title":"Gt160-246, a toxin binding polymer for treatment of Clostridium difficile colitis","volume":"45","author":"Kurtz","year":"2001","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Infectious Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552014000828?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552014000828?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T23:52:44Z","timestamp":1650930764000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891552014000828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":92,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S0891552014000828"],"URL":"https:\/\/doi.org\/10.1016\/j.idc.2014.11.005","relation":{},"ISSN":["0891-5520"],"issn-type":[{"value":"0891-5520","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Clostridium difficile Infections","name":"articletitle","label":"Article Title"},{"value":"Infectious Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idc.2014.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}